Crystalline forms of glucosylceramide synthase inhibitors and their uses
The development of stable crystalline forms of Compound 1, characterized by distinct XRPD patterns, addresses the need for improved stability and bioavailability, enabling effective pharmaceutical compositions for treating GCS-related diseases.
Patent Information
- Application Number
- JP2025510295
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-18
- Filing Date
- 2023-08-10
- Publication Date
- 2025-08-22
AI Technical Summary
There is a need for stable crystalline forms of the GCS inhibitor (E)-N-((1R,2R)-1-(3-chloro-4-cyclopropoxyphenyl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-2-(6-chloronaphthalen-2-yl)-2-(hydroxyimino)acetamide (Compound 1) with advantageous chemical and physical properties to ensure quality, safety, and efficacy in pharmaceutical applications.
The development of various crystalline forms, anhydrates, hydrates, solvates, and salts of Compound 1, characterized by specific X-ray powder diffraction patterns, including forms A, B, C, D, and their respective salts, such as L-malate and L-tartrate, to enhance stability and bioavailability.
The crystalline forms provide improved stability, reproducibility, and favorable physicochemical properties, facilitating the development of effective pharmaceutical compositions for treating GCS-related diseases.
Smart Images
Figure 2025527600000050 
Figure 2025527600000051 
Figure 2025527600000052